What Researching One Stock Actually Looks Like: A Walkthrough Using Johnson & Johnson

In a recent post, How to Research a Stock Before You Buy It, I walked through the framework — what to look for, what matters, and why. This post is meant to accompany that one with a real stock research example. Where the first post gave you the framework, this one shows you the framework in action.

After reading that first post, my son asked me a great question: “Okay, but what does this actually look like when you do it?” As a dad that meant a lot because one of the reasons I started this blog was the realization my kids were not receiving a lot of education tied to personal finance.

My son asked a fair question. A framework is one thing. Sitting down and looking at a real company is another.

So I am going to walk you through researching one stock — Johnson & Johnson, ticker JNJ — from start to finish. I will show you every type of information you can find, where to find it, and what each piece tells you. By the end you should have a clear picture of what serious stock research looks like in practice.

Please know I don’t look at all of these every time I am researching a new stock. Generally, I will have familiarity with a stock after listening to analysts discuss the company on CNBC. I generally have CNBC on much of the day so by the time I jump into a new stock I have heard a lot about the company.

This being said, it is important you understand the many ways you can evaluate a stock so this will be a very comprehensive post. From here, you decide what is important to you.

One important note before we start. I am not licensed to give investment advice and I will not be making a recommendation about Johnson & Johnson in this post. Full disclosure: I do own JNJ in my own portfolios, along with about 35 other individual stocks. I will be transparent about ownership whenever I discuss specific stocks in any substantive way. For JNJ specifically, I am genuinely a fan of the company — its decades of stability, its dividend reliability, and the broad usefulness of its products are reasons I personally chose to own it. But I am not telling you to buy or sell anything. The point of this post is to teach you how to look at any stock, including this one. What you decide to do with what you find is up to you (and, ideally, your financial advisor).

I picked Johnson & Johnson on purpose. It is large, widely covered, decades old, and has gone through enough real-world business events to make the research interesting. It recently spun off a major division. It carries ongoing legal exposure. It pays a dividend. It is exactly the kind of company where research actually matters — because the surface story is more complicated than the headline number.

Let’s get into it.

You Do Not Need a Brokerage Account to Do This

Here is something worth knowing right up front. You do not need a brokerage account to research a stock.

Most of the information we are about to discuss is sitting on the open internet, free, for anyone to read. CNBC, Yahoo Finance, Google Finance, the company’s own investor relations site, the SEC’s filings database — all of it is public. You can do a full, serious piece of research on any publicly traded company without ever logging into a brokerage.

This may surprise newer investors. The image people have is of someone hunched over a brokerage screen, deep in some proprietary analytics tool. The reality is that even active traders do most of their research outside of their brokerage. The brokerage is where the trade happens. The research happens on the internet, just like any other reading.

For me personally, CNBC is my go-to. I listen to it on the way to work. I scan the stock pages there for the basics. Yahoo Finance is a strong second source. I open my brokerage when I am ready to place a trade — not when I am still deciding.

So if you are reading this and you do not yet have a brokerage account, good. Do the research first. Decide whether you are ready to invest. Then open the account when it is time to act, not before.

Where to Start: The Basics

Before you look at anything else, you need to know what the company actually does. This sounds obvious, but a lot of new investors skip it. They hear a ticker, they like the price chart, they buy. Don’t do that.

In the first post, I made the case that the best place to start is with companies you already understand from everyday life — Peter Lynch’s idea that regular people often spot trends before Wall Street does. That principle applies here too, and Johnson & Johnson is still a good example, even with the Kenvue spinoff. Many of us have a family member who has been prescribed a J&J medication. Many of us have had a surgery involving J&J medical devices — orthopedic implants, surgical staplers, contact lenses, robotic surgery tools. If you know someone who has had a knee or hip replacement in recent years, there is a good chance J&J equipment was involved. Even before we look at a single number, we already have some sense of what kind of company this is. That familiarity is not a substitute for research — but it is a real starting point. (And if Band-Aid and Tylenol come to mind first, that is now Kenvue’s story — see below.)

For Johnson & Johnson, you can find a clean overview at three places:

• CNBC or Yahoo Finance — both have a company profile section that summarizes what the business does
• The company’s investor relations website (investor.jnj.com)
• The company’s Wikipedia page

What you are looking for in this first pass:

What does the company do?

Per the CNBC Company Profile:

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).

But for most of its history, J&J was three businesses under one roof — pharmaceuticals, medical devices, and consumer health. The consumer health business was the one most people grew up knowing: Band-Aid, Tylenol, Listerine, Neutrogena, Aveeno, Johnson’s baby powder. Those brands defined the J&J name for generations.

In 2023, J&J spun all of that off into a separate company called Kenvue (ticker KVUE). The decision was deliberate — J&J leadership wanted to separate the consumer retail business from the higher-margin, higher-growth medical and pharmaceutical business. The two have different customers, different competitors, different growth rates, and different risk profiles. Splitting them lets each company focus on what it does best.

What this means for your research: if you buy JNJ today, you are buying pharmaceuticals and medical technology only. You are NOT buying the consumer brands. Those now belong to Kenvue, which is a separate stock you can buy or not. We will come back to the spinoff later in this post, because it has important implications for how to read J&J’s historical numbers and for one significant ongoing risk.

How does it make money? Pharmaceuticals (prescription drugs) and medical technology (surgical and medical devices). After the Kenvue spinoff, J&J’s revenue is now in the range of $83 to $84 billion annually, down from around $99 billion before the split.

Where is it based? New Brunswick, New Jersey. United States company, listed on the New York Stock Exchange.

How long has it existed? Founded in 1886. That is not a small detail. A company that has survived nearly 140 years through depressions, wars, recessions, and industry transformations has institutional muscle that newer companies do not.

You can gather all of this in fifteen minutes, without logging into anything. None of it tells you whether to buy the stock. All of it tells you what you are actually looking at.

The Stock Price and What It Tells You (and Doesn’t)

Now look at the stock price.

Any finance site will show it to you. CNBC, Yahoo Finance, Google Finance, the Wall Street Journal — all free, all showing essentially the same number. The current price is just one number. The more useful view is the price over time.

Most charting tools let you toggle the time range — 1 day, 5 day, 1 month, 6 month, 1 year, 5 year, all-time. Look at all of them. Each one tells you something different.

The 1-day chart tells you almost nothing useful. It is for traders, not investors.

The 1-year chart shows you how the stock has performed recently. Is it up? Down? Flat? Volatile?

The 5-year chart shows you longer-term trend. Has it been generally climbing? Stalling? Falling?

The all-time chart shows you the full arc of the company’s history as a public stock.

Here is what you have to be careful about: stock price alone tells you very little. A stock at $150 is not “expensive” compared to a stock at $30. The price reflects how many shares exist and how the market is valuing the whole company. Two companies of identical value can have very different stock prices simply because one issued more shares than the other.

What price can tell you, looked at over time, is the market’s changing opinion of the company. A stock that has been flat for five years while the broader market has climbed is telling you something. A stock that has tripled in two years is telling you something. Neither tells you what to do — but both are worth understanding before you commit money.

Where the Numbers Live

Pull up JNJ on CNBC or Yahoo Finance — either works, they show essentially the same data. The amount of information sitting on that one page is genuinely incredible, and most people never look at it.

Here is what you will typically find:

Current price, daily change, daily range. Today’s number. Useful for context, not for decisions.

52-week range. The highest and lowest prices the stock has hit in the past year. This tells you how volatile the stock has been recently. JNJ is generally low-volatility — it does not swing as wildly as a small tech company. For JNJ, as of May 15, 2026, the range was $149.04 to $251.71. The stock had been trading near the upper end of that range, suggesting the talc litigation overhang may have eased or pharma fundamentals had been carrying the day.

Market capitalization. This is the total value the market currently assigns to the entire company. It is calculated by multiplying the share price by the total number of shares outstanding. For J&J, this is approximately $547.74 billion as of May 15, 2026. It puts the company in the “mega-cap” category — among the largest publicly traded companies in the world.

P/E ratio (price-to-earnings). We covered this in detail in the first post. As a quick refresher: it tells you how much you are paying for one dollar of the company’s annual earnings. Compare the P/E ratio to peers in the same industry — a P/E of 25 is high for an industrial company but low for a software company. Context matters.

For JNJ on May 15, 2026, the trailing P/E was approximately 26. That is on the higher side of J&J’s historical range, which has more typically been in the 15 to 20 area — investors were paying more for each dollar of earnings than they have at most points in the past decade.

Forward P/E. Same idea, but based on projected future earnings instead of actual past earnings. Useful, but remember it is based on estimates, not facts. For JNJ, this number is currently telling an interesting story: trailing P/E of about 26 versus forward P/E of about 19. That gap means analysts expect earnings to grow meaningfully over the next year. The gap itself is information — it shows where the market thinks the company is headed, not just where it has been.

Dividend yield. If the company pays a dividend, this tells you what percentage of the current stock price you would receive each year in dividend payments. For JNJ on May 15, 2026, the yield was approximately 2.36 percent. J&J is what is called a “Dividend King” — a company that has raised its dividend every year for more than 50 consecutive years. That kind of track record is rare and meaningful. (Recall from the first post: an unusually high dividend yield can be a warning sign, not a buying signal.)

EPS (earnings per share). The company’s total net earnings divided by its total outstanding shares. This is the denominator of the P/E ratio. For JNJ on May 15, 2026, trailing twelve-month EPS was approximately $8.65, and the annual dividend was about $5.36 per share — meaning the company was paying out roughly 60 percent of its earnings as dividends. That is a healthy and sustainable payout ratio.

Beta. A measure of how volatile the stock is compared to the overall market. A beta of 1 means it moves roughly with the market. A beta of 0.5 means it moves about half as much. A beta of 2 means it moves about twice as much. J&J’s current beta is approximately 0.26 — meaning the stock historically moves only about a quarter as much as the broader market. That is exceptionally low. It is one of the reasons J&J is often described as a defensive stock — it tends to hold up better than the market during downturns, and it also tends to participate less in big rallies. For a long-term investor looking for steady ownership through volatile periods, that is a feature, not a bug. For someone hoping for fast gains, it is the opposite.

Volume. How many shares traded today. High-volume days often signal something happened — news, earnings, a major announcement.

Another comment about volume — if a company has very little stock volume, it does not take as much to move the stock to the upside or downside.

Each of these pieces of information is one click away on any free finance site. Most investors look at price and ignore all of it.

A practical note: no single site has everything for free. When I was researching this post, I used CNBC for the basics — price, market cap, P/E, dividend yield, beta — and then bounced over to Yahoo Finance for the analyst consensus data, because CNBC requires a paid Pro subscription for that particular piece. This is normal. Real-world research means moving between two or three free sites to get the full picture. It is not a problem; it is just how this works.

A bonus if you have a brokerage account: most major brokerages add their own proprietary equity rating to the stock page. Schwab grades stocks A through F. Fidelity has equity ratings. Morningstar (integrated into most brokerages) provides star ratings and a fair-value estimate. These are nice extras when you have access to them — but they are not requirements. The core research can all be done on free public sites.

What the Analysts Say

Beyond the basic page data, dozens of professional analysts publish research and ratings on Johnson & Johnson. You can see a summary of analyst opinions at:

• Yahoo Finance (the “Analysis” tab on any stock page)
• MarketWatch
• Seeking Alpha (some paid, some free)
• Your brokerage’s research page, if you have one

You may find minor discrepancies between sites but what you typically see:

Consensus rating — usually shown as “Buy,” “Hold,” or “Sell,” sometimes with finer gradations like “Strong Buy” or “Overweight.”

Number of analysts covering the stock — for a company like J&J, this is typically 20-25 analysts.

Average price target — what the average analyst thinks the stock will be worth 12 months out.

High and low price targets — the most optimistic and most pessimistic targets among the analysts.

Take these with several grains of salt. Analysts are often wrong. They also tend to herd — when one major firm moves their rating, others sometimes follow. But the range of opinions can be useful. If 20 analysts cover a stock and they range from “this will go to $200” to “this will go to $250,” there is broad agreement. If they range from “$120 if the lawsuits hit” to “$280 if the new drug pipeline delivers,” there is real disagreement — and that disagreement is itself information.

For Johnson & Johnson on May 15, 2026, here is what the analyst picture looked like at Yahoo Finance: 25 analysts covered the stock. The consensus rating was a Buy, with the breakdown roughly 5 Strong Buy, 9 Buy, 10 Hold, and 1 Sell. The average 12-month price target was about $253, which implied roughly 11 to 12 percent upside from the then-current price of about $227. That is a fairly bullish picture overall — not a single major firm calling for the stock to fall sharply, decent agreement that there is upside, but enough Holds in the mix to suggest there is not unanimous enthusiasm either.

A personal observation on ratings

Here is something I want to share from personal experience, because it changed how I think about ratings.

Across the roughly 35 stocks I currently own in one of the accounts I manage, only 2 are rated A by Schwab’s model — Apple and Bristol Myers Squibb. The rest range from B all the way down to D. You might assume that means most of my portfolio is questionable. The opposite has been true.

Bristol Myers, my A-rated stock, is actually one of the few in my portfolio sitting at a small unrealized loss based on where I bought it. Meanwhile, Broadcom (rated D) has been one of my best performers. Palo Alto Networks (also rated D) has roughly doubled since I purchased it.

Apple, the other A, has done well — but Apple has done well for nearly everyone who has owned it for the past decade, regardless of ratings.

I am not telling you that Broadcom and Palo Alto Networks are great stocks to buy today. They might not be. I am telling you this: quantitative rating models — Schwab’s and most others — tend to favor stable, predictable, mature businesses with steady earnings. That is not where the highest returns usually come from. The highest returns often come from companies the model penalizes for being volatile, fast-growing, or in transition. AVGO and PANW are exactly that kind of company.

The lesson is not “low ratings are good and high ratings are bad.” That would just be another oversimplification. The lesson is: ratings are inputs, not verdicts. Read them. Understand what model produced them and what that model rewards and penalizes. Then make your own decision.

Compared to What? Looking at the Competition

Here is something most beginners skip, and it changes the entire picture once you understand it: no stock exists in isolation. Every number we have looked at for Johnson & Johnson — the P/E ratio, the dividend yield, the growth rate, the profit margins — only means something when you compare it to similar companies.

A forward P/E ratio of 17 sounds reasonable on its own. But if every other major pharmaceutical company is trading at a forward P/E of 12, then JNJ is expensive relative to peers. If they are all trading at 22, JNJ is cheap. The number itself is the same. The context changes everything.

For Johnson & Johnson, the comparable companies fall into two groups, because J&J is one of the few large companies that operates meaningfully in both pharmaceuticals and medical devices:

Pharmaceutical peers: Pfizer (PFE), Merck (MRK), Eli Lilly (LLY), AbbVie (ABBV), Bristol Myers Squibb (BMY), Novartis (NVS), AstraZeneca (AZN).

Medical device peers: Medtronic (MDT), Stryker (SYK), Abbott Laboratories (ABT), Boston Scientific (BSX).

You do not have to research every one of these companies in the depth we just did on J&J. You just need to compare a handful of the key numbers.

What to look at when comparing:

• P/E ratio — cheap or expensive vs. peers?
• Revenue growth — growing faster or slower than peers?
• Dividend yield — higher or lower than peers?
• Profit margins — better or worse than peers?
• Market capitalization — bigger or smaller than peers?

Where to find this comparison: both CNBC and Yahoo Finance have a “Competitors” or “Comparable Companies” tab on every stock page. Click it. You will see a side-by-side comparison of the basic metrics for the company and its closest peers, all on one screen. It takes about two minutes.

What you are looking for is not necessarily “which stock is best.” You are looking for context. If J&J is trading at a 30 percent discount to its peers, you want to understand why — is the market pricing in the talc lawsuits? Is its growth slower? Is something else going on? If J&J is trading at a premium, the same question in reverse: what is it doing that justifies paying more?

Sometimes the right answer is to buy the peer, not the stock you started researching. That is not a failure of the research. That is the research working.

The Earnings Report

This is where most casual investors stop reading, and it is where serious research actually begins.

Every public company is required to report its financial results every quarter (every three months) and every year. These are called earnings reports, and they are the most important documents in stock research.

In the first post I mentioned the 10-K (annual report) and 10-Q (quarterly report). Here is where they earn their keep. For Johnson & Johnson, you can find them at investor.jnj.com under “Financials” or “Quarterly Results.” You can also find them on the SEC’s website at sec.gov by searching “Johnson & Johnson.”

What to look for in an earnings report:

Revenue. Total sales. Up from last year? Down? Why? (Remember the Zoom example from the first post — context matters more than the raw direction.)

Earnings. Net profit after all expenses. The number that drives the P/E ratio. Up, down, or flat compared to the same quarter last year?

Earnings guidance. What management expects for the rest of the year. Raised? Lowered? Maintained?

Segment breakdown. For a company like J&J, this shows how much revenue and profit came from pharmaceuticals versus medical technology. If one segment is growing rapidly and the other is shrinking, that matters.

Management commentary. The CEO and CFO typically host a conference call after each earnings release. The transcripts are usually available within a day. Reading what management actually says — and what questions analysts push back on — is genuinely educational.

If you want to go deep, the 10-K contains everything: detailed financials, business description, risk factors, legal proceedings, executive compensation, and outlook. It is long. It is dry. It is also the most honest document any public company puts out, because lying in a 10-K is a federal crime.

For Johnson & Johnson specifically, the 10-K is where you will find the most detailed disclosure about ongoing litigation — including the talc lawsuits we are about to discuss.

The Hard Stuff: Lawsuits and Litigation Risk

Here is where it gets real. Johnson & Johnson is involved in a massive ongoing legal situation involving claims that its talc-based baby powder caused ovarian cancer and mesothelioma. As of mid-2026, there are more than 60,000 cases consolidated in the federal multidistrict litigation, and the total number of talc-related claims nationwide — including state court filings — is over 90,000. Individual jury verdicts have ranged from hundreds of thousands of dollars to over a billion dollars per case. In December 2025, a Maryland jury awarded $1.5 billion to a single mesothelioma plaintiff — the largest single-plaintiff verdict in the history of the litigation. The same month, a California jury awarded $40 million to two women with ovarian cancer in the first of three bellwether test trials there.

You cannot research Johnson & Johnson without understanding this.

But here is what I want you to take away more than any specific number: this situation is genuinely fluid. By the time you are reading this, the case counts will have moved. There may have been new verdicts, new settlement talks, new appeals decided. The story keeps changing. A massive California verdict of $966 million was reduced to $16 million on appeal in March 2026 when a judge struck the punitive damages portion. Settlement talks were scheduled in April 2026 to try again at a global resolution. None of this is settled, and what I write here today may be partially out of date by the time you read it. That is exactly why ongoing monitoring matters — which we will talk about later in this post.

In the first post, I listed common red flags to watch for. Material litigation was not explicitly on that list — but it absolutely belongs there, and the J&J case is a clear example. When a company faces tens of thousands of lawsuits with potential liability in the billions, that risk has to be understood and weighed.

Where to find current information on the litigation:

• The company’s own 10-K and 10-Q filings (the “Legal Proceedings” section)
• Major financial news outlets — CNBC, Wall Street Journal, Reuters, Bloomberg, Google Search
• Legal industry news sites that specialize in mass torts

What you are looking for is not whether the lawsuits are “fair” or “unfair.” You are looking for:

• How much has the company reserved against potential liability?
• What is the range of analyst estimates for total settlement cost?
• What has the company tried, and what has worked or failed? J&J attempted three separate bankruptcy filings through subsidiaries (most recently through a subsidiary called Red River Talc) to resolve all claims at once and cap total liability. All three were ultimately rejected by federal judges. With the bankruptcy strategy now exhausted, individual trials have resumed across the country, and the company is back in the position of fighting cases one by one — which is what produced the recent billion-dollar verdicts.
• How is the litigation reflected in the current stock price?

This is the kind of risk you cannot see on a stock chart. You can only see it by reading. But the numbers and the legal proceedings are only part of the story. There is something else worth looking at when researching any company, and J&J’s history makes this an especially good place to talk about it.

Reading the Company, Not Just the Numbers

Here is something the numbers will not tell you, but that serious investors learn to watch for: how a company responds when something goes wrong.

Every company faces a crisis eventually. A product defect. A lawsuit. A regulatory action. A scandal. The crisis itself is often less revealing than what comes next — because the response is where the company’s actual culture shows up. Strong cultures put the public first, even when it costs them money. Weak cultures protect the balance sheet, even when it costs them their reputation.

A company that got it right: Tylenol, 1982

Johnson & Johnson actually has one of the most famous crisis-response stories in American business history. In 1982, seven people in the Chicago area died after taking Extra-Strength Tylenol capsules that had been laced with cyanide. The tampering happened after the product left J&J’s control — someone had bought bottles from store shelves, contaminated them, and returned them. J&J was not at fault.

Despite that, J&J pulled every Tylenol product from every shelf in America. About 31 million bottles. Over $100 million in 1982 dollars. They worked openly with law enforcement. They communicated transparently with the public. They eventually re-released Tylenol in new tamper-resistant packaging — the foil seal under the cap on every medication you buy today is a direct result of that decision. The brand recovered. And J&J built a reputation for putting public safety ahead of short-term profit that lasted for decades.

(One note: Tylenol is now owned by Kenvue, the consumer health company J&J spun off in 2023. But the corporate identity that made the 1982 decision is the same J&J that exists today.)

A company that got it wrong: Boeing 737 MAX, 2018-2019

One quick disclosure before I go further: I own Boeing stock as well. I include this case because it is one of the clearest recent examples of how a major company can mishandle a crisis.

In 2018 and 2019, two Boeing 737 MAX aircraft crashed within five months of each other, killing 346 people. The cause was eventually traced to a flight-control software system that could push the nose of the plane down in certain conditions without pilots understanding what was happening. The fix was technical. The response was a failure.

Boeing initially insisted the aircraft was safe and that there was no engineering or technical problem. The CEO publicly blamed poor pilot training. Governments around the world eventually grounded the planes — but only after months of pressure, additional scrutiny, and growing public outrage. Crisis-communications experts later described Boeing’s handling as slow, legalistic, and lacking empathy. Internal documents that emerged later painted a picture of a culture that had drifted from engineering excellence toward financial optimization.

The contrast with J&J’s Tylenol response is extreme. One company pulled a product it had not even tampered with, at enormous cost, to protect the public. Another company defended a product its own engineers had concerns about, and hundreds of people died before the planes were grounded.

Boeing’s stock has spent years recovering. More importantly, the company’s reputation as a gold-standard American engineering firm has been deeply damaged in ways the financial numbers will not fully capture for years to come.

Where does the current J&J talc situation fit?

Somewhere between those two examples, and reasonable people disagree where.

This connects to a point from the first post: bad news can sometimes be a buying opportunity. Sometimes. The discipline is in telling the difference between a temporary problem and a real one. Some investors look at J&J’s talc response and see legitimate corporate defense against an aggressive plaintiff bar in a country with no caps on jury awards. Others look at the same facts and see a company more focused on legal containment than on the kind of decisive public-first action that defined the 1982 Tylenol response. The bankruptcy attempts have been particularly controversial — some see them as efficient settlement mechanisms, others see them as attempts to shield the company from rightful claims.

I am not telling you what to conclude. I am telling you that this question — how is the company responding, and what does that say about its culture — is part of the research.

The broader lesson

When you are researching any stock, look at how the company has responded to its hardest moments. Read about its biggest crises. Pay attention to whether leadership led with transparency or with legal posture. Whether they protected the public or protected the balance sheet. Whether they took responsibility quickly or fought it for years.

These are not always either/or — companies face real constraints, and crisis response is genuinely hard. Plaintiff lawyers do sometimes pursue weak claims. Regulators do sometimes overreach. But the pattern over time tells you something the financial statements never will. A company that handles bad news well tends to keep doing so. A company that handles it poorly tends to repeat that pattern in different forms.

Add this to your research. How did they handle their last crisis? How are they handling the current one? What does that tell you about the next one?

The Spinoff Story

Another piece of the J&J picture that surface-level research will miss: the Kenvue spinoff.

In 2023, J&J split off its consumer health division as a separate publicly traded company called Kenvue (ticker KVUE). Kenvue now owns all the consumer brands — Band-Aid, Tylenol, Listerine, Neutrogena, Aveeno, Johnson’s baby powder, and others. J&J kept pharmaceuticals and medical technology.

Why does this matter for research?

Historical comparisons require an extra step. If you look at J&J’s revenue trend over five years, you might initially worry that a major business division leaving the company would make the numbers impossible to compare. The good news: most major financial sites and the company’s own financial reports publish “pro forma” or “as restated” historical numbers that retroactively exclude the consumer health business, so the comparisons are apples to apples. As of this writing, CNBC’s income statement for J&J shows revenue moving from approximately $80 billion in 2022 to $94 billion in 2025 — a clean, growing trend on continuing operations. That is a more useful view than the raw reported numbers, which would show an artificial drop in 2023 when Kenvue actually left. The thing to watch for is whether you are looking at the adjusted or unadjusted version. If revenue ever “falls off a cliff” in a single year on a multi-year chart, that is your signal to check whether a spinoff or divestiture has been properly adjusted for in the comparison.

The company you are looking at today is not the company you remember. J&J today is a higher-margin, higher-growth, more focused company than the diversified conglomerate it was a decade ago. It is also more concentrated in a higher-risk industry.

The talc liability stayed with J&J. The consumer health brands went with Kenvue, but the legal exposure from talc lawsuits remained with J&J. This is worth knowing.

Spinoffs, mergers, divestitures — these are the kinds of events that make historical research genuinely complicated. They are also the kinds of events that long-term investors have to understand.

The Dividend

Johnson & Johnson is one of the most reliable dividend-paying stocks in the entire market. It has raised its dividend every year for more than 60 consecutive years, which puts it in an elite category called Dividend Kings (companies with 50+ years of consecutive dividend increases).

For someone researching the stock, here is what to look at — and this builds on the dividend section from the first post:

Current dividend yield. What percentage of the stock price do you receive annually in dividends. Available on any finance site. As of May 15, 2026, the JNJ dividend yield is 2.36 percent.

Payout ratio. What percentage of the company’s earnings is being paid out as dividends. A payout ratio of 50% means the company is paying out half of its earnings; 100% means all earnings go towards dividends; over 100% means it is paying out more than it earns, which is not sustainable long-term. JNJ pays approximately 60% of its earnings out as dividends.

Dividend history. How long has the company been paying a dividend, and how steadily has it grown?

Dividend coverage. How comfortable is the company’s cash flow relative to the dividend obligation? Found in the cash flow statement of the 10-K.

A reliable, growing dividend is one of the most valuable features a stock can have for long-term investors. It is also not a reason by itself to buy a stock — a company in decline can pay a dividend right up until it cuts the dividend, at which point the stock typically falls hard. (As noted in the first post, watch out for unusually high yields — those can be warning signs, not buying signals.)

One other key fact about dividends. When purchasing a dividend paying stock you will have the option to reinvest the dividend — or not. Reinvesting means that any money received as a dividend is used to buy more shares of the same stock. Historically I reinvest but once I retire I will likely change this and live off dividends.

A Quick Note Before the Table: Start With What Matters

Before I show you the snapshot, one important framing point.

Most stock research articles throw 25 metrics at you and expect you to absorb them all. That is not how this works in real life. A beginner does not need to understand beta and price-to-book ratio to make a thoughtful first decision about whether to own a stock. A beginner needs to understand what the company does, how it has been priced recently, whether it makes money, whether it pays a dividend, and what major risks it carries. That is enough.

So I am going to organize what we have learned into three levels:

Essential — if you do not know these, you are not researching. Start here.

Helpful — useful context. Add these as you build comfort.

Advanced — meaningful when you are comparing similar stocks, sizing a position, or thinking about volatility. Worth learning. Not where you start.

You do not need to fill in everything to do good research. You need to fill in enough. For most beginners, the Essentials alone put you ahead of 90 percent of people who buy stocks.

Why the Advanced Metrics Matter (Even If You Skip Them for Now)

I want to make one quick case for the Advanced fields before we move on, because they are not just “extra.” They matter — they just matter later.

Take average daily volume as an example. On paper it sounds like trivia: how many shares of this stock trade hands on a typical day. For a stock like Johnson & Johnson — which trades millions of shares every single day — the number barely matters to an individual investor. You can buy 100 shares of JNJ and the market will not notice.

But that same metric for a small, thinly traded stock is critical. If a company only trades 5,000 shares a day on average, your decision to buy or sell even a modest position can move the price meaningfully. Worse, you might find that when you want to sell, no one is buying — and you have to lower your asking price significantly to find a buyer. This is called liquidity risk, and it is one of the quiet ways people lose money in lesser-known stocks without ever realizing the risk was there.

Beta is another one that seems abstract until it is not. A stock with a beta of 0.7 (less volatile than the market) and a stock with a beta of 1.8 (much more volatile than the market) can look identical on a one-day price chart. But during a market downturn, the high-beta stock will fall much harder. If you are years from retirement, you might not care. If you are six months from retirement, beta might be the most important number on the page.

These metrics are not “advanced” because they are harder to understand. They are advanced because they matter most depending on your situation. As you grow as an investor, you will find yourself reaching for them naturally.

For now, focus on the Essentials. The rest will come.

Stock Research Example: Pulling It All Into One View

Here are the Essentials for someone researching JNJ on May 15, 2026, alongside a blank column for you to fill in with whatever the numbers look like on the day you are reading this.

Johnson & Johnson Essential Research Snapshot

Metric	JNJ on May 15, 2026	JNJ Today	Where to find it
What does the company do?	Pharmaceuticals and medical technology		CNBC, Yahoo Finance, investor relations
Current stock price	$226.71		CNBC, Yahoo Finance
52-week low	$149.04		CNBC, Yahoo Finance
52-week high	$251.71		CNBC, Yahoo Finance
Market capitalization	$547.74 billion		CNBC, Yahoo Finance
P/E ratio (trailing)	26.2		CNBC, Yahoo Finance
Dividend yield	2.36%		CNBC, Yahoo Finance
Most recent quarterly revenue	$24.06 billion (Q1 2026)		Earnings release, 10-Q, Yahoo Finance
Most recent quarterly earnings	$5.24 billion (Q1 2026)		Earnings release, 10-Q, Yahoo Finance
Material ongoing litigation	Talc litigation — 60,000+ MDL cases, 90,000+ total nationwide; bankruptcy attempts have failed; bellwether trials underway; situation actively evolving		10-K ‘Legal Proceedings,’ Google Search
Recent restructurings	Kenvue spinoff (consumer health) completed 2023		10-K, press releases, news

If you are reading this post weeks, months, or years after May 15, 2026, every number in the first column will have changed. That is the point. The methodology in this post is timeless — the data is not. Pull up JNJ on CNBC or Yahoo Finance right now and fill in the second column. That is exactly the exercise this post is meant to teach.

Want the full worksheet, including Helpful and Advanced fields?

I built a downloadable Excel worksheet you can use to research any publicly traded stock. It includes everything in the table above plus the Helpful and Advanced fields we discussed, color-coded by level so you know where to start. The worksheet has hints on where to find each piece of information, and a notes column for your own observations.

Print it, fill it out by hand, or open it in Excel and type the numbers in. Either way, by the time you finish even the Essential rows, you will have done more research on that stock than most people who buy it.

After the First Time: Staying Current Without Doing Everything Again

Everything we have walked through up to this point is what you do the first time you seriously look at a stock — when you are deciding whether to own it, or when you have just bought it and want to truly understand what you own.

Here is the good news: you do not have to do all of this every time.

Once you have done the full workup once, staying current on the company is easier. The companies you own — or are seriously watching — change incrementally. New earnings come out every quarter. Litigation status updates. Management changes. Major announcements. But the foundational picture you built does not need to be rebuilt from scratch each time.

What you need is a way to know when something material happens, so you can pay attention without having to constantly check.

Three tools that make this almost effortless:

Google Alerts. Go to google.com/alerts. Type in the company name or ticker. Choose how often you want to be emailed (immediate, daily, or weekly). Google will send you an email any time new content matching that search shows up on the web. Free, simple, and the easiest possible way to stay current on a company. I recommend setting one up for every stock you own.

A watchlist on CNBC or Yahoo Finance. Both sites let you create a watchlist of stocks you follow. Once you set this up, you get emails when there is news about your companies, when earnings are released, when analysts change their ratings. It is the simplest way to maintain awareness without actively looking.

Earnings calendars. CNBC, Yahoo Finance, and many other sites publish earnings calendars showing when each company is scheduled to report. Knowing in advance when a company you own is reporting earnings lets you actually plan to read the release rather than missing it.

There is also a more advanced option for serious investors: the SEC’s website at sec.gov lets you subscribe to RSS feeds for any public company, so you get notified of every filing — 10-Ks, 10-Qs, 8-Ks (which are filed for material events), insider trading reports, everything. This is overkill for most people but valuable for anyone who wants to be on top of every official disclosure.

My personal approach: Google Alerts on the companies I own, a CNBC watchlist for the same, and I listen to CNBC throughout the day. That combination keeps me current with very little active effort. When something big happens, I know about it within a day, and I can decide whether to do deeper work or just file it away.

The point is this: the first-time workup is real work. Maintaining your awareness is not. Once you have done the hard part, staying informed is just a matter of letting the right information come to you.

Putting It All Together

We have just covered a lot of ground. Let me list everything we found on Johnson & Johnson without using anything but free public websites and a few minutes of patience:

• What the company does and how it makes money
• Its full corporate history including a recent major restructuring
• Current stock price, 52-week range, and long-term price history
• Market capitalization
• P/E ratio (current and forward)
• Dividend yield, dividend history, and dividend reliability
• EPS, beta, trading volume
• Analyst consensus ratings, number of analysts, and price target ranges
• How J&J compares to its pharmaceutical and medical device peers
• Quarterly and annual earnings reports
• Management’s forward guidance
• Segment breakdown of revenue and profit
• Detailed legal proceedings and litigation risk
• How the company has historically responded to crisis (Tylenol, 1982)
• How that compares to crisis response at other major companies (Boeing 737 MAX)
• The history and implications of the Kenvue spinoff
• Payout ratio and dividend coverage
• How to stay current on the company going forward without redoing all of this.

All of that is publicly available. All of it is free. All of it was sitting there before you started looking. You did not need a brokerage account, a subscription, or any special tools.

Most people who buy stocks do not look at most of this. They look at the price chart and the ticker symbol and they click buy.

You can do better.

A Final Word

I want to repeat what I said at the top: nothing in this post is a recommendation about Johnson & Johnson. I have not told you whether to buy, hold, or sell. I have not told you whether the talc litigation is over-priced or under-priced into the current stock. I have not told you whether the Kenvue spinoff made J&J a better or worse investment.

Also as I mentioned at the top, I am personally a fan of J&J for the reasons we have walked through — the dividend history, the decades of stability, the breadth of the business. That is a personal view, not advice. Your situation, your goals, and your timeline are different from mine, and what works for me may not work for you.

I have shown you where to look.

Stock research is not magic. It is reading. It is patience. It is the willingness to spend two hours understanding a company before you spend $5,000 buying a piece of it. Most investors will not do this work. The ones who do tend to make better decisions over time — not because they are smarter, but because they are informed.

The next time you are about to buy a stock, sit with it for an evening. Pull up the quote page on CNBC or Yahoo Finance and read. Skim the most recent news and earnings release. Look at the 52-week range. Check the dividend history. Read about any ongoing legal or business risks.

Then decide.

You will not be right every time. Nobody is. But you will be making your decisions with your eyes open — and that, more than any single stock pick, is what separates investors from gamblers.

———

Johnson & Johnson is used in this post solely as a real-world example to demonstrate research methodology. Nothing in this post constitutes investment advice, a recommendation to buy or sell any security, or a solicitation of any kind. I am not a licensed financial advisor. Please consult a qualified professional before making investment decisions.